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shows degeneration and major loss of
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Human pluripotent stem cells (PSCs) provide a
unique entry to study species-specific aspects of hu-
man disorders such as Alzheimer’s disease (AD).
However, in vitro culture of neurons deprives them
of their natural environment. Here we transplanted
human PSC-derived cortical neuronal precursors
into the brain of a murine AD model. Human neurons
differentiate and integrate into the brain, express 3R/
4R Tau splice forms, show abnormal phosphoryla-
tion and conformational Tau changes, and undergo
neurodegeneration. Remarkably, cell death was
dissociated from tangle formation in this natural 3D
model of AD. Using genome-wide expression anal-
ysis, we observed upregulation of genes involved in
myelination and downregulation of genes related to
memory and cognition, synaptic transmission, and
neuron projection. This novel chimeric model for
AD displays human-specific pathological features
and allows the analysis of different genetic back-
grounds and mutations during the course of the
disease.
INTRODUCTION
Alois Alzheimer described in 1906 the main pathological hall-
marks of Alzheimer’s disease (AD): amyloid-b (Ab) plaques,1066 Neuron 93, 1066–1081, March 8, 2017 ª 2017 Elsevier Inc.neurofibrillary pathology and tangles, astrogliosis, and neuronal
loss (Alzheimer, 1906). Cerebrovascular amyloid angiopathy, mi-
crogliosis, inflammation, and major synaptic alteration are other
pathological features of AD (Katzman, 1986; McGeer et al., 1988;
Crews and Masliah, 2010; Spillantini and Goedert, 2013).
Theamyloid hypothesis links abnormally foldedAbpeptides ina
linear and causal cascade to the other disease hallmarks,
includingneuronal tangle formationandneuronal cell death (Hardy
and Selkoe, 2002; critique in De Strooper and Karran, 2016). This
hypothesis has provided the theoretical basis for the generation of
numerous animal models, diagnostics, and therapeutics for AD.
However, evolving insights have made increasingly clear that a
more complex theory and more elaborate in vivo models are
needed to understand the long prodromal phase of the disease
(De Strooper and Karran, 2016). Rodent AD models (Ashe and
Zahs, 2010; LaFerla and Green, 2012) usually overexpress
mutated forms of the familial AD (FAD)-causing genes APP and/
or PSEN, leading to extensive amyloid plaque deposition, Ab-as-
sociated neuroinflammation, and some synaptic dysfunction.
However, crucial aspects of the disease process, like neuronal
tangle formation and severe neuronal loss, have never been
convincingly demonstrated in rodents (Kokjohn and Roher,
2009;Morrissette et al., 2009;Crews andMasliah, 2010). The rele-
vance of these genetic models to study sporadic AD, where pa-
tients do not carry mutations in APP or PSEN, is debated.
Human embryonic stem cells (ESCs) and patient-derived
induced pluripotent stem cells (iPSCs) allow modeling of human
neurological disease in a human genetic context (Brennand
et al., 2015; Pas¸ca et al., 2014; Vera and Studer, 2015; van den
Ameele et al., 2014; Dolmetsch and Geschwind, 2011). Neurons
derived from iPSCs of FAD patients showed altered Ab42/Ab40
ratio and abnormal Tau phosphorylation (Yagi et al., 2011; Israel
et al., 2012; Shi et al., 2012; Kondo et al., 2013; Choi et al., 2014;
Muratore et al., 2014; Hu et al., 2015). Recently, a three-dimen-
sional, human neural stem-cell-derived culture (Choi et al., 2014)
displayed Ab plaque-like structures and Tau silver-positive ag-
gregates (Choi et al., 2014). The cells overexpress exogenous
APP and PSEN FAD genes. No cell loss was detected, and neu-
roinflammatory and vascular components of the disease are
lacking in this in vitro model. It remains, indeed, crucial to com-
plement in vitro approaches with in vivo experiments to study
human neurons in the context of the diseased brain.
Neural precursors derived from pluripotent stem cells (PSCs)
(reviewed in Suzuki and Vanderhaeghen, 2015) can be trans-
planted into the rodent brain, resulting in specific patterns of
cortical neuronal maturation, connectivity, and synaptic activity,
well beyond what can be achieved in a purely in vitro condition
(Gaspard et al., 2008; Espuny-Camacho et al., 2013; Michelsen
et al., 2015). We use here this approach to investigate whether
Ab species generated in an AD mouse model (Radde et al.,
2006) are sufficient to induce full AD pathology in non-affected,
genetically non-manipulated human neurons. This chimeric
model presents numerous Ab plaques and Ab-associated neuro-
inflammation in the human transplant and, importantly, the trans-
planted neurons show remarkable signs of neurodegeneration
that are not detected in the mouse host brain or in transplanted
PSC-derived mouse neurons. Thus, human neurons respond to
Ab pathology differently than their murine counterparts in vivo.
RESULTS
Human-Grafted Neurons Integrate into the Mouse Brain
and Are Exposed to Amyloid-b
Wedifferentiated GFP-expressing humanPSCs into cortical pre-
cursor cells in vitro to implant them as xenografts into the brains
of newborn mice (Figure 1A; Figures S1E and S1F) (Espuny-Ca-
macho et al., 2013). We used transgenic Tg (Thy1-APPSw,Thy1-
PSEN1*L166P) 21Jckr, further called APP/PS1-21, mice (Radde
et al., 2006) and crossed them with immunodeficient
NOD.CB17-Prkdcscid/J, further called NOD-SCID mice (Shultz
et al., 1995), to generate AD mice or wild-type (WT) littermates
suitable for grafting experiments (Espuny-Camacho et al.,
2013). We additionally used GFP-expressing mouse neurons
derived from murine PSCs as controls (Figures S2H and S2I)
(Gaspard et al., 2008).
The cells present a normal karyotype (Figure S1D) or compar-
ative genomic hybridization (CGH) array (data not shown) and
undergo neuronal and telencephalic/cortical specification
in vitro as attested by beta III tubulin, Tau, Tbr1, and Ctip2 stain-
ing (Figures S1A–S1C). The transplanted human neurons ex-
press GFP and human-specific markers, like HuNuclei (Figures
S1G and S1H), and present cortical (Tbr1+, CTIP2+, Satb2+,
and Brn2+), telencephalic (Foxg1+), and mature neuronal
(NeuN+ and MAP2+) identities (Figures 1B–1G; Figures S1I and
S1J). Electron microscopy (EM), combined with GFP-immuno-
gold labeling, shows numerous synapses between the human
graft and the mouse host (Figures 1H and 1I). RNA sequencing
(RNA-seq) analysis confirms broad expression of telencephalic,
cortical, and glutamatergic, and some expression of GABAergic,astrocytic, and oligodendroglia genes (Figure S1K). Cholinergic,
dopaminergic, or neural crest-derived cell identities are less
abundant or absent (Figure S1K).
Ab plaques are present in the ADmouse host brain (GFP nega-
tive), as assessed by Thioflavin, 6E10, and Congo red staining
(arrows; Figures 1L–1N; Figures S2A–S2E). Congo red+ plaques
show birefringence when using plane-polarized light (Fig-
ure S2E). Importantly, Ab plaques are detected within GFP+
human neuronal clusters (arrowheads; Figures 1L–1M0; Figures
S2A–S2B0, S2D, and S2E) and near single human neuronal cells
integrated into the mouse host tissue (arrows; Figure 1N; Fig-
ure S2C). Ab plaques within human clusters are more diffuse
than mouse host dense-cored plaques and are significantly
smaller (Figure 1O; 120 ± 6 mm2 in mouse host; 88 ± 8 mm2 in hu-
man grafts). No significant differences in number of Ab plaques
per unit surface are detected (Figure 1P; 40 ± 3 plaques/mm2 in
mouse host; 71 ± 16 plaques/mm2 in human grafts). Ab reactivity
is, as expected, not observed in WT mice (Figures 1J and 1K).
Ab plaque ultrastructure is very similar in the human trans-
plants and in the mouse host: one or more cores of extracellular
Ab filaments (asterisks) surrounded by dystrophic neurites (DNs)
(arrowheads) (Figures 1Q–1T). Immunogold labeling against hu-
man cell-specific markers, i.e., the GFP transgene or endoge-
nous STEM121 marker, confirms that Ab deposits (asterisk)
and dystrophic neurites are within grafted human clusters
(arrowheads point to immunogold particles; Figures S2F and
S2G). PSC-derived mouse neurons transplanted under similar
conditions also present Ab plaques and DNs inside murine clus-
ters (Figures S2H–S2K).
Thus, the transplanted neuronal clusters integrate into the
mouse host tissue and are exposed to Ab deposits produced
by the AD mice.
Amyloid-b-Associated Neuroinflammation in the Human
Neuronal Transplants
We detect GFAP+ astrocytes (Figures 2A, 2B, 2E, and 2F) and
Iba1+ microglia cells (Figures 2C, 2D, 2G, and 2H) clustered
around Thioflavin+ Ab deposits in mouse host tissue (GFP;
arrows) and human grafts in AD mice (GFP+; arrowheads). Sig-
nificant increases in the number of GFAP+ astrocytes and Iba1+
microglial cells are seen in AD versus WT mice (Figures 2M and
2N), but neuroinflammation inmouse host and human transplants
does not differ significantly. Microglia cells performing phagocy-
tosis are detected (red arrowhead; Figure 2K). Astrocytes and
microglial cells within human clusters are mostly of host origin as
attested by the lack of GFP immunoreactivity (arrowheads; Fig-
ures 2I–2L). Ultrastructural analysis of astrocytes and microglia
cells in human clusters in ADmice showanactivated hypertrophic
morphology with 76% and 74% of cells showing enlarged and/or
phagocytic phenotypes, respectively (Figures 2P and 2R–2V).
These phenotypes are rarely found in human grafts in WT mice
(Figures 2O, 2Q, 2T, and 2V), indicating that the elicited immune
response is induced by the Ab-associated pathology and not a
consequence of unexpected host-graft reactivity.
Thus, both grafted human neuronal clusters and mouse host
tissue are similarly exposed to Ab-associated neuroinflamma-
tory responses characterized by astrocytic and microglial cell
reactivity and recruitment to the Ab plaque sites.Neuron 93, 1066–1081, March 8, 2017 1067
Figure 1. Human-Grafted Neurons Integrate
into the Mouse Brain and Are Exposed to Ab
(A) Schematic representation of the experimental
outlay.
(B–G) GFP+-grafted human neurons stained with
the GFP antibody (green, B–G) and with the
cortical deep layer markers Tbr1 (B) and CTIP2 (C),
the upper layer markers Satb2 (D) and Brn2 (E), the
telencephalic marker FoxG1 (F), or the mature
neuronal marker MAP2 (G).
(H and I) Electron microscopy combined with GFP
immunogold (arrowheads) shows synaptic con-
tacts from the human transplant to the mouse host
tissue (H) and reverse (I) 4 MPT.
(J–N) GFP (green) and Thioflavin-S (red) stainings
show Ab plaques within human transplants (ar-
rowheads) and in mouse host tissue (arrows) in AD
mice (L–N), but not in WT mice (J and K), 4 MPT.
(M0) relates to (M). (N) shows an isolated GFP+
neuron close to Ab plaques (arrows).
(O and P) Quantification of Ab plaque mean area
(O) and of the number of Ab plaques per area (P) in
mouse host (n = 5) and human grafts (n = 5) in AD
mice 4MPT. Data are represented asmean ± SEM,
Student’s t test: **p < 0.01, n.s., non-significant.
(Q–T) EM images show Ab deposits (asterisks)
within human transplants or mouse host tissue in
AD mice 4 MPT. Scale bars, 25 mm (B–G and J–N),
500 nm (H and I), 2 mm (Q), 1 mm (R), 10 mm (S), and
5 mm (T).
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Extensive Neuritic Dystrophy and Alterations of
Synaptic Markers Surrounding Ab Plaques in Human
Neuronal Transplants
We examined the grafted human neuronal clusters exposed to
Ab for signs of cellular or neuritic abnormalities. DN structures
are found associated with Ab plaques in both mouse host and
human grafts in AD mice 4 months post-transplantation (MPT)
(Figures 3A, 3B, 3D, and 3E), but not in WT mice (Figures 3C
and 3F). DNs present a globular structure (Figures 3B and 3E)
and a heterogeneous content of vesicles (red boxes), dense
bodies (red arrowheads), mitochondria (blue boxes), and neuro-
filaments (green boxes) (Figures 3G–3N). Myelin alterations are
also detected (arrowheads; Figures S4K and S4L).
Ubiquitin staining confirms the presence of DNs around
Thioflavin+ Ab plaques in mouse host tissue and human clusters
4 MPT (Figures 3O–3R) with 85% of Ab plaques surrounded by
DNs in human grafts versus 58% in mouse host (Figure 3S).
DNs are also detected in human clusters in AD mice by GFP or
human-specific STEM121 staining (arrowheads; Figures 3O,
4C, and 4J; Figures S2L and S2M) but are absent in human grafts
in WT mice (Figures 4A and 4H). We observe abnormal accumu-
lations of the presynaptic markers synaptophysin (SYP) and ve-
sicular glutamate transporter 1 (VGlut1) around Ab plaques in hu-
man clusters in AD mice (Figures 4C, 4D, 4J, and 4K), similar to
the accumulations found in human AD brains (Brion et al., 1991)
(Figures S3A–S3D). These accumulations are absent in human
clusters in WT mice (Figures 4A, 4B, 4H, and 4I) and are less
important in mouse host or in mouse neurons grafted in AD
mice (Figures 4E, 4F, 4L, and 4M; Figures S3E–S3H), with 74%
and 70% of Ab plaques in human grafts surrounded by SYP
and VGlut1+ structures, respectively, versus 23% and 39% in
mouse host (Figures 4G and 4N). The dendritic marker MAP2 re-
veals an area devoid of staining around Ab plaques in human
clusters in AD mice (Figures 4O and 4P) that is minor in mouse
host (Figures 4Q and 4R). The absence of MAP2 is mirrored by
the accumulation of SYP+ or Tau+ structures around Ab plaques
(Figures S3I–S3P). The postsynaptic marker Homer1 confirms
the reduction of dendritic staining around Ab plaques in human
neuronal clusters (Figures S3Q–S3T).
Thus, DNs surrounding Ab plaques display abnormal accumu-
lations of presynaptic and axonal proteins, while human den-
dritic and postsynaptic proteins become reduced. These neuritic
changes are much more subtle in mouse host tissue or mouse
neuronal clusters grafted in the AD mice.Figure 2. Ab-Associated Neuroinflammation in the Human Neuronal G
(A–H) Representative micrographs of mouse host tissue (A–D) and GFP+ human gr
associated with Thioflavin+ Ab plaques (blue) 4 MPT and 6 MPT. Arrows and a
respectively.
(I–L) GFP astrocytes and microglial cells (arrowheads; I–L) are present inside
arrowhead; K).
(M and N) Quantification of the number of GFAP+ astrocytes (M) or Iba1+ microglia
AD: n = 3 animals 4 MPT, n = 4 animals 6 MPT) and human grafts (WT: n = 3 anima
Data are represented as mean ± SEM, two-way ANOVA with Bonferroni post-tes
(O–V) Ultrastructure of hypertrophic reactive astrocytes (P and S) and reactive m
reactive astrocytes and microglia in WT mice (O and Q) and phagocytosing micro
grafts in AD mice. The cytoplasm of these cells has been outlined (O–U). DN, d
showing hypertrophic and/or phagocytic morphology in human grafts in WT (n =
Student’s t test: ****p < 0.0001. Scale bars, 25 mm (A–L), 2 mm (P–S), and 5 mm (O
1070 Neuron 93, 1066–1081, March 8, 2017Major Degeneration and Loss of Human Neurons In Vivo
Robust neuronal loss is a crucial AD hallmark lacking from exist-
ing animal models (Kokjohn and Roher, 2009; Morrissette et al.,
2009; Crews and Masliah, 2010). Remarkably, the density of hu-
man neurons at 6 MPT, evaluated using GFP together with the
pan nuclear marker TOPRO3 (Figures 5A–5F) or HuNuclei (Fig-
ures S4A–S4F), is much lower in transplants in AD mice (Figures
5D–5F) than in WT mice (Figures 5A–5C), although similar
amounts of cells were injected. In contrast, nuclei density is
similar in mouse host tissue in AD (Figures 5J–5L) versus WT
mice (Figures 5G–5I).
Quantification shows that the density of mouse host tissue
neurons is not significantly changed (98% in AD versus 100%
inWT) while the density of human neurons in ADmice is reduced
to 54% compared to WT animals (Figure 5M). The density of hu-
man neurons at 2 MPT—before Ab plaques are detected—is not
different between AD and WT animals (Figure 5M). Thus, the hu-
man cells integrate normally and similarly in WT and AD mouse
brain following transplantation and cell loss occurs specifically
in AD animals at later stages when Ab pathology is present
in vivo.
Semithin sections of human transplants stained with tolui-
dine blue also show dense Ab plaques, disorganized neuropil
texture, and reduced neuronal density in AD mice (Figures 5N
and 5O), while no such morphological alterations are seen
in mouse host tissue and PSC-derived mouse grafts in
AD mice. On the contrary, many healthy-appearing neurons
are detected near Ab plaques (Figures 5P and 5Q; Figures
S4I and S4J). Ultrastructural analysis and quantification of
neuron density confirm a significant decrease in the number
of neurons in human grafts in AD at 6 MPT (Figure 5W;
1,463 ± 64 neurons/mm2 in grafts in WT versus 344 ± 31 neu-
rons/mm2 in grafts in AD) and the absence of significant
differences in mouse host tissue at this age (Figure 5W;
925 ± 47 neurons/mm2 in host in WT versus 817 ± 37 neu-
rons/mm2 in host in AD).
Importantly, up to 33% of human neurons in AD mice show a
necrotic phenotype (Figure 5X) characterized by electron lucent
nuclei with highly dispersed chromatin, swelling of cytoplasm,
and swelling and disintegration of cytoplasmic organelles (Fig-
ures 5S–5T0) (Naganska and Matyja, 2001; Ueda et al., 2007;
Burattini and Falcieri, 2013). Enlarged mitochondria with disrup-
ted cristae (red arrowheads), large vacuoles (blue arrowheads),
and even rupture of the nuclear membrane (green arrowheads)rafts
afts (green, E–H) in ADmice. GFAP+ astrocytes or Iba1+microglia cells (red) are
rrowheads show Ab plaques in mouse host tissue and within human grafts,
human grafts. Notice host, GFP, reactive microglia in phagocytic state (red
cells (N) per area in mouse host (WT: n = 3 animals 4MPT, n = 4 animals 6MPT;
ls 4 MPT, n = 4 animals 6 MPT; AD: n = 3 animals 4 MPT, n = 4 animals 6 MPT).
ts: *p < 0.05; **p < 0.01; ***p < 0.001.
icroglia (R and U) in human grafts 4 MPT and 6 MPT in AD mice. Notice non-
glia adjacent to dystrophic neurites (R) or degenerating material (U) in human
ystrophic neurite; m, microglia. Quantification of the percentage of glial cells
3) and AD (n = 3) mice 6 MPT (T and V). Data are represented as mean ± SEM,
and U).
Figure 3. Neuritic Dystrophy Surrounding Ab Plaques in Human Neuronal Transplants in AD Mice
(A–F) Ultrastructure of dystrophic neurites (DNs, arrowheads) around Ab plaques (asterisks) in human grafts and mouse host tissue in AD mice (A, B, D, and E).
Ultrastructure of axons (red arrowheads) and dendrites (blue arrowheads) in human grafts and mouse host tissue in WT mice (C and F).
(G–N) Heterogeneous content of DNs in human grafts and mouse host: accumulations of vesicles (red boxes; G and H), dense bodies (arrowheads; I and J),
mitochondria (blue boxes; K and L), and neurofilaments (green boxes; M and N).
(O–R) Ubiquitin+ DNs (red) around Thioflavin+ Ab plaques (blue) in GFP+ human grafts (green in O and P) and mouse host tissue (Q and R) in AD mice 4 MPT.
(S) Quantification of the percentage of Ab plaques surrounded by ubiquitin+ DNs in mouse host (n = 5) and human grafts (n = 5) in AD animals 4 MPT. Data are
represented as mean ± SEM, Student’s t test: ****p < 0.0001. Scale bars, 25 mm (O–R), 5 mm (A), 2 mm (B, D–F, J–L, and N), 1 mm (C, G, I, and M), and 500 nm (H).
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Figure 4. Specific Accumulation of Neuritic/Synaptic Markers around Ab Plaques in Human Neuronal Grafts in AD Mice
(A–N) Representative images of human clusters in WT and ADmice and ADmouse host tissue stained with GFP (green; A, C, E, H, J, and L), Thioflavin (blue; A–F
and H–M), and synaptophysin (SYP, red; B, D, and F) or VGlut1 (red; I, K, and M) 4 MPT. SYP+ and VGlut1+ accumulations around Ab plaques in GFP+ human
clusters in AD mice (arrowhead; D and K). Minor accumulations in mouse host tissue in AD mice (arrow; F and M). Quantification of the percentage of Ab plaques
surrounded by SYP+ or VGlut+ accumulations in mouse host (n = 5) and human grafts (SYP: n = 5, VGlut1: n = 4) in AD mice (G and N). Data are represented as
mean ± SEM, Student’s t test: **p < 0.01; ****p < 0.0001.
(O–R) Representative images of human clusters andmouse host tissue in ADmice stainedwithGFP (green; O andQ), Thioflavin (blue; O–R), andMAP2 (red; P and
R) 4 MPT. GFP+ human clusters show lack of MAP2 around Ab plaques (arrowheads), while minor effects were detected in the mouse host tissue (arrows). Scale
bars, 25 mm (A–R).
1072 Neuron 93, 1066–1081, March 8, 2017
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are also seen (Figures 5S0–5T0). However, such phenotypes are
completely absent in human neurons in WT mice (Figures 5R,
5R0, and 5X). The effects appear human specific as no signs of
degeneration are observed in mouse host tissue or in PSC-
derived mouse neurons in AD mice (Figures 5V and 5X; Fig-
ure S4N). Apoptotic cell death does not contribute strongly to
the cell loss at this stage as no increased caspase-3-activated
staining (data not shown) or TUNEL labeling is observed (Figures
S4O–S4Z).
Overall, the human grafts exposed to Ab undergo major
neuronal loss and neurodegeneration in vivo via a necrosis-
mediated mechanism. Moreover, this effect is species specific
as mouse host neurons or grafted mouse neurons exposed to
the same Ab load do not undergo degeneration.
Gradual Appearance of the 4R Tau Splicing Form in
Human Neurons In Vivo
Adult murine brain mainly expresses the 4R Tau isoform con-
taining four microtubule-binding repeats. During human brain
embryonic development, only the 3R splice form of Tau is de-
tected, while the adult human brain expresses 3R and 4R Tau
splice forms in a 1:1 ratio (Goedert and Jakes, 1990). We thus
studied the expression pattern of Tau using specific anti-
bodies raised against 3R or 4R Tau splice forms (Figures
S5M and S5N). After 2 and 4 MPT, 3R Tau is expressed, but
4R Tau is detected only in 0.7% of the human neurons
(GFP+ or STEM121+), while 4R Tau is widely expressed in
mouse host tissue (Figures 6A–6B0, 6E–6F0, and 6M; Figures
S5A–S5C). However, at 6 MPT, 89% of the human neurons ex-
press high levels of 4R together with 3R Tau (arrows; Figures
6I–6J0 and 6M; Figures S5G–S5I). In addition, RNA-seq anal-
ysis of human grafts in old animals (8 MPT) shows a 3R/4R
Tau expression close to 1, similar to the ratio in adult human
brain (Figure 6N).
We wondered whether the appearance of 4R Tau could be
accelerated in our model using two human iPSC lines derived
from a patient carrying the pathogenic Tau mutation Ex10+16Figure 5. Neurodegeneration and Neuronal Loss in Human, but Not in
(A–L) Representative images of human grafts (A–F) and mouse host tissue (G–L)
marker TOPRO3 (red) 6 MPT. Areas devoid of TOPRO3+ cells are evident within th
clusters and in surrounding host tissue (arrowheads and arrows, E). In contras
presence of Ab plaques (arrows, K). Human grafts andmouse host tissue inWTmi
(M) Percentage of relative cell density (number of nuclei per area) of mouse host tis
n = 4 animals; WT: n = 3 animals), human neurons 6 MPT (AD: n = 4 animals; WT
animals) in AD animals compared to the density inWT animals expressed as 100%
tests: **p < 0.01, ***p < 0.001, n.s., non-significant.
(N–Q) Toluidine blue-stained semithin sections of human clusters and mouse h
accumulation of dense Ab plaques (asterisks), disorganized neuropil texture, an
mouse host tissue (Q) show accumulation of dense Ab plaques (asterisks) but n
mouse host (P). Arrowheads point to neurons.
(R–V) Ultrastructure of grafted human andmouse host neurons inWT andADmice
of neurodegeneration consistent with necrosis are specifically observed in huma
human neurons grafted inWTmice (R and R0) or in mouse host neurons (U and V).
structures, and disrupted nuclear membranes, respectively.
(W) Quantification of neuronal density expressed as the number of neurons per are
MPT. Data are represented as mean ± SEM, two-way ANOVA with Bonferroni po
(X) Quantification of the percentage of dying neurons in mouse host (WT: n = 3,
mean ± SEM, two-way ANOVA with Bonferroni post-tests: ****p < 0.0001; n.s., no
U, and R0), and 1 mm (S0 and T0).
1074 Neuron 93, 1066–1081, March 8, 2017(further indicated as Tau*) (Sposito et al., 2015). This mutation
is considered to favor 4R Tau expression and causes Fronto-
temporal dementia (FTD) (Hutton et al., 1998). Following in vivo
transplantation, human Tau* neurons (HuNCAM+) showed no
4R Tau expression at 2 MPT (Figures 6C–6D0). However, at 4
MPT 37% of the human Tau* neurons expressed 4R together
with 3R Tau isoforms (arrows; Figures 6G–6H0 and 6M; Figures
S5D–S5F) in agreement with previous findings in vitro (Sposito
et al., 2015). At 6 MPT, 84% of Tau* neurons highly expressed
4R together with 3R Tau (arrows; Figures 6K–6L0 and 6M; Figures
S5J–S5L).
Human Tau* neurons transplanted into the AD mouse brain
show similar phenotypes as described above. We detect
numerous Ab plaques within the grafts (Figures S6A–S6H) and
DNs (Figures S6I and S6J). SYP+ and VGlut+ accumulations
are surrounding Ab plaques (Figures S6K–S6L0). Importantly,
the density of grafted human Tau* neurons near Ab plaques is
reduced to 28% compared to WT animals (Figure 5M; Figures
S6M–S6R). Toluidine blue-stained semithin sections (Figures
S6S and S6T) and EM analysis (Figures S6U and S6V) confirm
neuronal loss and necrosis that are not seen in human Tau* neu-
rons in WT mice.
Thus, major AD human-specific pathological hallmarks are re-
produced with iPSC-derived human neurons from a FTD patient
transplanted into AD mice.
Presence of Pathological Tau Species in Human
Neurons In Vivo
We analyzed Tau pathology in the grafted human neurons. AT8+
hyperphosphorylated forms of Tau are found in the cell bodies of
human neurons and human Tau* neurons (arrowheads; Figures
7B and 7E) and in DNs adjacent to Ab plaques (arrowheads; Fig-
ures 7C and 7F) at 8 MPT in AD mice. Staining is similar to that
found in AD human brain (arrows; Figures S7J–S7O) and in AD
mouse tissue (arrowheads; Figures 7H and 7I). In fact, more
than 95% of Ab plaques show AT8+ DNs in mouse host, human
grafts, and human Tau* grafts (Figure 7S).Murine, Transplants in AD Mice
in WT and AD mice stained with GFP (green), Thioflavin (blue), and the nuclear
e human grafts in ADmice (F) together with abundant Ab plaques within human
t, homogeneous staining of mouse nuclei is seen in AD mice (L), even in the
ce show homogeneous staining of nuclei (C and I) and no Ab plaques (B and H).
sue neurons (AD: n = 4 animals; WT: n = 4 animals), human neurons 2MPT (AD:
: n = 4 animals), and human Tau* neurons 6 MPT (AD: n = 3 animals; WT: n = 3
. Data are represented asmean ± SEM, one-way ANOVAwith Bonferroni post-
ost tissue in WT and AD mice 6 MPT. Human clusters in AD mice (O) show
d reduced neuronal density compared to human clusters in WT mice (N). AD
o gross changes in neuropil texture or reduced cell density compared to WT
6MPT. (R0), (S0), and (T0) relate to (R), (S), and (T). DN, dystrophic neurites. Signs
n neurons grafted in AD mice (S, S0, T, and T0) while no signs are observed in
Red, blue, and green arrowheads point to degenerating mitochondria, vacuolar
a in mouse host (WT: n = 3, AD: n = 3) and human grafts (WT: n = 3, AD: n = 3) 6
st-tests: ****p < 0.0001; n.s., non-significant.
AD: n = 3) and human grafts (WT: n = 3, AD: n = 3) 6 MPT. Data are shown as
n-significant. Scale bars, 25 mm (A–L), 50 mm (N–Q), 5 mm (R, T, and V), 2 mm (S,
Figure 6. Temporal Pattern of 3R and 4RTau
Expression in Human Neurons Grafted
In Vivo
(A–L0) Grafted human neurons (A, B, E, F, I, and J)
detected with GFP (green) or grafted human Tau*
neurons (C,D,G,H,K,andL)detectedwithHuNCAM
(green) and stained for 4R Tau (red) after 2, 4, and 6
MPT. Higher-magnification images are shown in
A0–L0. Arrows show 4R Tau+ human neurons.
(M) Quantification of the percentage of 4R Tau+
cells in human grafts (n = 3 animals 4 MPT; n = 6
animals 6–8 MPT) and human Tau* grafts (n = 4
animals 4 MPT; n = 2 animals 6–8 MPT). Data are
represented as mean ± SEM, two-way ANOVA
with Bonferroni post-tests: **p < 0.01, ***p < 0.001.
(N) Quantification of the RNA-seq data for 3R/4R
Tau ratio in human grafts in young (4–5 MPT) (n = 5
WT, 7 AD) and old (8MPT) (n = 2WT, 5 AD) animals.
Results are shownasmean±SEM,Student’s t test:
***p < 0.0001. Scale bars, 25 mm (A–L0).Importantly, MC1+, which reveals a pathological Tau con-
formation, is also detected in few cell bodies of human neurons
and human Tau* neurons (arrowheads; Figures 7K and 7N;NFigures S7A–S7C0), and more than 96%
of Ab deposits show MC1+ DNs at 8
MPT in human clusters in AD mice (arrow-
heads; Figures 7L, 7O, and 7T; Figures
S7D–S7F0), similarly to human AD brain
(arrows; Figures S7P–S7U) (Weaver
et al., 2000). However, no MC1 staining
is found in mouse host tissue in AD mice
(Figures 7Q, 7R, and 7T; Figures S7G–
S7I0), as previously described (Kokjohn
and Roher, 2009; Morrissette et al.,
2009). The lack of MC1 reactivity in AD
mouse host is probably not explained by
human specificity of the antibody as it
also labels mouse Tau in a pericyte-defi-
cient APP transgenic mouse model (Sa-
gare et al., 2013). No AT8 orMC1+ staining
is detected in WT mice (Figures 7A, 7D,
7G, 7J, 7M, and 7P).
Cytoskeletal alterations with abnormal
accumulation of straight 10-nm-wide neu-
rofilaments are detected in DN of human
neurons in AD mice 6–8 MPT (Figures
S7V and S7V0). In addition, Hirano bodies,
paracrystalline inclusions with an array of
symmetrically organized 8–10 nm fila-
ments, are also present (Figures S7W
and S7W0). However, abnormal filaments
in the form of paired helical filaments or
twisted ribbons have not been detected.
These results show that even after 6–8
MPT the human neurons do not present
definite tangle pathology although clear
hyperphosphorylation and pathologicalconformational alterations of Tau are observed. Thus, there is
major neurodegeneration even in the absence of full-spread
tangle pathology in the human neurons.euron 93, 1066–1081, March 8, 2017 1075
Figure 7. Tau Hyperphosphorylation and
Abnormal Tau Conformational Changes in
Grafted Human Neurons
(A–R) Immunohistochemistry with AT8 (brown; A–I)
or MC1 (brown; J–R) of human grafts, human Tau*
grafts, mouse host tissue, and non-grafted mouse
brain tissue in WT and ADmice. AT8+ neuronal cell
bodies (arrowheads; B and E) and DNs around
Congo red+ Ab deposits (pink, asterisks) (arrow-
heads; C, F, H, and I) in human grafts (B and C),
human Tau* grafts (E and F), andmouse host tissue
(H and I) in AD animals. MC1+ neuronal cell bodies
(arrowheads; K and N) and DNs around Congo
red+ Ab deposits (pink, asterisks) (arrowheads; L
and O) are found in human grafts and human Tau*
grafts in AD mice, but not in mouse host tissue (Q
and R). Arrowheads point to soma and DNs+
structures. Asterisks mark Congo red+ Ab plaques.
Counterstaining with hematoxylin (blue).
(S and T) Percentage of Ab plaques surrounded
by AT8+ (S) and MC1+ (T) DNs in human grafts
(n = 4), human Tau* grafts (n = 3), and mouse host
tissue (n = 3) in AD mice. Results are shown as
mean ± SEM, one-way ANOVA with Kruskal-Wallis
test, ****p < 0.0001; n.s., non-significant. Scale
bars, 50 mm (A–R).
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Transcriptome Analyses Reveal Human-Specific
Signatures of AD
To assess global transcriptional changes in the human grafts
in AD versus WT mice, we performed RNA-seq analysis at
two time points: 4–5 MPT (young mice) and 8 MPT (old
mice). Global analyses of gene expression patterns reveal inter-
esting alterations in several gene ontology (GO) categories (Ash-
burner et al., 2000). Genes involved in synaptic transmission,
gated channel activity, and neuron projection (GO:007268,
GO:0022836, and GO:0043005) are significantly downregulated
at 8 MPT in human neurons in AD versus WT mice (Figure 8A;
Figure S8; Table S5). Additionally, genes involved in cognition
and learning and memory (GO:0050890 and GO:0007611)
also show a trend toward downregulation. GO categories
related to immune or inflammatory response (GO:0002376 and
GO:0006954) show a non-significant upregulation. It should be
noted that our analysis includes only the human gene expression
programs in the transplanted neurons and not the murine-
derived immune cells of the brain (Figure 8A; Figure S8). Genes
from the GO category regulation of cell death (GO:0010941)
are upregulated at 8 MPT. Representative genes among these
categories are shown in Figure 8B. Significant differential
expression of mRNAs and non-coding RNAs is detected already
at early, but more at late, stages in human transplants in AD
versus WT mice (Tables S2–S5; for raw counts see Tables S6
and S7). Interestingly, among the most strongly upregulated
genes in the human neurons in AD mice at 8 MPT (Table S4)
are a couple of non-coding RNA genes: LINC01007 and RP11-
89N17.4. Genes involved in myelination (MOBP, MAG, UGT8,
MOG, andMBP) are also upregulated in the transplanted human
cells. Alterations in myelination are known to occur in AD (Ettle
et al., 2016; Bartzokis, 2011), but few studies have investigated
the role of oligodendrocytes and myelin in AD (De Strooper
and Karran, 2016; Bartzokis, 2011). In the list of downregulated
genes, we find OTOF, GABRE, TAC1, PTK2B, and CACNA1H
involved in neurotransmission and RHGAP36 involved in vesicle
transport and regulation (Table S5). Interestingly COL25A1, also
known as CLAC, is downregulated (Table S5). CLAC specifically
binds to fibrillized Ab and is present in Ab plaques in AD patients
(Hashimoto et al., 2002; Tong et al., 2010).
To further evaluate the relevance of our model for human AD,
we compared the gene expression data from human neurons
with a published dataset of human AD samples (Zhang et al.,
2013). We performed co-expression clustering analysis using
WCGNA (Langfelder and Horvath, 2008), yielding modules of
genes showing a similar expression pattern across samples (Fig-
ure 8C). This analysis generated 37 modules from human trans-
plants. The overlap of genes of these modules (left column) with
the modules identified by Zhang et al. (2013) (right column) is
determined using a Fisher’s exact test. These data demonstrate
that the transplanted human neurons show transcriptional
changes in gene modules that are also affected in the human
AD brain (Zhang et al., 2013).
DISCUSSION
The generation of better in vivo models that closely resemble
the pathological features present in the human AD brain isinstrumental to test new hypotheses with regard to AD etiology
and for the validation of new therapeutic approaches. Ideally,
such a model would incorporate a human genetic background,
be versatile and robust, and include aspects such as innate
inflammation, cellular heterogeneity, and minimal use of trans-
genes to drive the pathogenesis (De Strooper and Karran, 2016).
The main purpose of the current work was to ask to what
extent a human/mouse brain chimera could be used to model
critical aspects of AD previously uncovered by rodent models.
We transplanted cortical neuronal precursors differentiated
from one normal ESC line (H9) and from two FTD iPSC lines
derived from the same patient into the brain of a well-character-
ized AD mouse model. Although three cell lines is a limited num-
ber, all displayed similar profound degeneration and necrosis
when exposed to Ab in a large number of independent transplan-
tation experiments. In addition, the human-specific pathology
was compared with host mouse neurons and transplanted
PSC-derived murine neurons, which show much more resis-
tance to Ab pathology than the human neuronal counterparts.
At 4 MPT, already the human neurons show many signs of
neurodegeneration. Dystrophic structures are found and presyn-
aptic components, like synaptophysin and vesicular glutamate
transporter 1, accumulate, while the dendritic marker MAP2
and the postsynaptic marker Homer1 disappear around Ab
plaques.
At 6 MPT, a significant loss of human neurons is found to an
extent that has never been reported for mouse neurons in the
many existing models for AD. Neuronal density is strongly
reduced (down to 54%) in human grafts in AD versus WT mice
whereas no significant differences were observed in mouse
host tissue. Importantly, at 2 MPT, similar densities of human
neurons are observed in AD and WT mice, indicating that inte-
gration is normal, and cell loss occurs only later over the course
of the disease. EM analysis revealed that 33% of human neurons
in AD mice show signs of degeneration at 6 MPT. The cell loss
appears to be mostly necrotic based on morphological criteria.
Genome-wide expression analysis of human transplants (8
MPT) shows, however, upregulation of a broader category of
genes related to regulation of cell death. This GO category con-
tains many genes that are only indirectly involved in the regula-
tion of cell death processes. Further work will be needed to
clarify whether some of the altered genes play causal roles in
the cell death process that we observed here.
Strikingly, this major neurodegeneration and human neuronal
loss occur in the absence of detectable tangle pathology. It
was recently suggested that the induction of neuronal tangles
critically depends on the expression of 4R Tau as seen in the hu-
man adult brain (Choi et al., 2014). At 2 and 4 MPT, the human
neurons express mainly 3R isoforms, but after 6 MPT, 4R Tau
isoforms are expressed in 89% of the human neurons. In addi-
tion, the 3R/4R Tau ratio in human neurons comes close to 1
at 8 MPT, as seen in the adult human brain, in contrast with
most in vitro iPSC-derived models. We detect AT8 hyperphos-
phorylation and, notably, MC1 pathological conformational
changes in Tau (Jicha et al., 1997) that are not detected in murine
AD models. iPSCs expressing the Tau mutation Ex10+16 linked
to FTD (Sposito et al., 2015) show an earlier appearance of 4R
Tau and a higher tendency to cell death when exposed to Ab.Neuron 93, 1066–1081, March 8, 2017 1077
Figure 8. Transcriptional Changes in Human Neurons Grafted In Vivo
(A) Genes ranked according to the significance of the differential expression of upregulated (purple) and downregulated (blue) genes for young (4–5 MPT) and old
(8 MPT) human grafts. The x axis shows the enrichment score according to the Gene Set Enrichment Analysis (GSEA). Significance of enrichment: ***p < 0.001;
**p < 0.01; *p < 0.05.
(B) Log fold change of differential expression (brown: downregulation; green: upregulation) of a selected set of genes in young and old samples. p values are
corrected for multiple testing: ***p < 0.001; **p < 0.01; *p < 0.05.
(C) WCGNA co-expression modules compared to the modules from Zhang et al. (2013). Four extra gene sets (prefix: DE) from the most differentially expressed
genes (up and down in old and young mice) are included. Significance of overlap was determined by a Fisher’s exact test and Benjamini-Hochberg multiple
testing correction. The plot depicts the 22 modules (out of a total of 37) that show a significant overlap with the Zhang modules, indicating the best matching
Zhang module on the right. The bars indicate the adjusted p value.
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The data are in line with the idea that Tau expression is crucial for
Ab-induced toxicity in AD transgenic animals (Roberson et al.,
2007; Leroy et al., 2012). However, we did not detect Tau tangles
after 8 MPT in human neurons or in human Tau* neurons. Likely,
even longer periods in vivo are required for detectable tangle pa-
thology, or additional seeding is needed to induce the tangle
conformation. The NOD-SCID background needed for the ex-
periments unfortunately does not allow analysis beyond 8 MPT
due to increased incidence of graft-unrelated tumor formation.
Recently, a three-dimensional in vitro AD model with human
neuronal stem cells that overexpress mutated FAD genes was
reported (Choi et al., 2014). This model uses matrigel as a 3D
support matrix for the cells and recapitulates Ab pathology.
The model also presents pathological Tau phosphorylation and
Tau filaments but fails to show neurodegeneration or cell death.
We have not modified our neurons with APP or PSENmutations,
and neurons were grown within the brain, which is arguably a
more natural situation than the matrigel used in the cell culture
system. It is intriguing that Tau aggregation was detected in
the cell culture system without neurodegeneration. Further in-
vestigations are needed to better understand the relationship,
if any, between abnormal Tau conformation and cell death.
A particularly important aspect of the current approach is that
innate immunity, believed to play an important role in AD (Heneka
et al., 2015), remains apparently intact in the model. As shown,
host-activated astrocytes and microglia cells are recruited to
the human transplants, and similar neuroinflammatory responses
are observed in human clusters andmouse host. Activatedmicro-
glia cells have been proposed as essential for the cell loss in AD
(Fuhrmann et al., 2010), and this might explain the lack of cell
loss in the 3D cell culture system discussed above. In further ex-
periments, it should be relevant to study how the loss of function
of microglia cells in the host affects neurodegeneration in the hu-
man neurons in vivo (Fuhrmann et al., 2010).
Lastly, our model allows a genome-wide transcriptome anal-
ysis of the human neurons exposed to Ab at early and late stages
of the disease in vivo. Intriguingly, we observe two non-coding
RNA sequences among the most upregulated genes. RP11-
89N17.4 expression might be altered in AD patients (Gui et al.,
2015), and data from our lab show dysregulation of LINC01007
in AD patients (data not shown). While these findings are still pre-
mature, it should motivate additional work exploring the role of
non-coding RNAs in neurodegeneration (Salta and De Strooper,
2012). We also notice that COL25A1 is downregulated at late
stages. Interestingly, rare variants in COL25A1 have been asso-
ciated with healthy aging and possible protection against AD
(Erikson et al., 2016). Other upregulated genes are involved in
cell death and myelination, while many downregulated genes
are implied in memory and cognition, synaptic transmission,
gated channel activity, neurotransmitter levels, and neuron pro-
jection. We validated our model comparing our results with the
results of a previous genome-wide gene expression study of
AD patient brains (Zhang et al., 2013). The good concordance,
taking into account that Zhang et al. (2013) provided data on total
brain blocks from patients while we analyzed gene expression
changes in human neurons specifically, is encouraging.
In conclusion, we present here a novel in vivo approach to
investigate AD mechanisms in human neurons by generating amouse/human brain chimera. This approach opens the door to
explore how different human genetic backgrounds modulate
AD-related features in vivo. The model is also of interest to
further investigate whether and how Ab modulates Tau pathol-
ogy and how this affects neurodegeneration. This initial work
demonstrates clearly the importance of a human molecular
and cellular background to observe full neurodegeneration in
the presence of Ab plaques.
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6E10 Covance Research Products Cat# SIG-39320-1000 RRID: AB_10175145
AT8 Thermo Fisher Scientific Cat# MN1020 RRID: AB_223647
B3Tubb Covance Research Products Cat# PRB-435P-100 RRID: AB_291637
B3Tubb Covance Research Products Cat# MMS-435P RRID: AB_2313773
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GFAP Dako Cat# Z0334 RRID: AB_10013382
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Anti-mouse biotinylated Vector Laboratories Cat# BA-2000 RRID: AB_2313571
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Anti-rabbit 488 Thermo Fisher Scientific Cat# A-11034, also A11034 RRID:
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Anti-rabbit 594 Thermo Fisher Scientific Cat# A21207 RRID: AB_141637
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Anti-rabbit 568 Thermo Fisher Scientific Cat# A-11011, also A11011 RRID:
AB_143157
Anti-rabbit 647 Thermo Fisher Scientific Cat# A-21245, also A21245 RRID:
AB_2535813
Anti-rabbit biotinylated Vector Laboratories Cat# BA-1000 RRID: AB_2313606
Anti-rabbit Ultrasmall 0.8 nm IgG Aurion Cat# 800.011 RRID: AB_2632383
Anti-chicken 488 Thermo Fisher Scientific Cat# A-11039 RRID: AB_2534096
Anti-chicken 555 Thermo Fisher Scientific Cat# A-21437 RRID: AB_2535858
Anti-chicken 647 Thermo Fisher Scientific Cat# A-21449 RRID: AB_2535866
Anti-guinea pig 647 Jackson ImmunoResearch Laboratories Cat# 106-605-003 RRID: AB_2337446
Biological Samples
Human AD brain samples Brion, J.P., ULB, Brussels Buee, L., and
Caillierez R.,, University of Lille, France
N/A
Chemicals, Peptides, and Recombinant Proteins
ROCK inhibitor Calbiochem Cat# Y-27632
Noggin R&D Systems Cat# 1967-NG-025
Critical Commercial Assays
Apop Tag Plus in situ apoptosis fluorescein
detection kit
Chemicon/Millipore Cat# S7111
Silver enhancement kit HQ Silver Nanoprobes Cat# 2012
Deposited Data
RNA-seq raw featurecounts from human
PSC-derived neurons grafted into the
cortex of AD and WT mice
This paper Table S6
RNA-seq raw featurecounts from murine
AD and WT cortex
This paper Table S7
Experimental Models: Cell Lines
Human ESC H9 line stably transduced
with GFP
H9 (WA09) original line (Thomson et al.,
1998)WiCell Research Institute H9-GFP line
was generated by Espuny-Camacho et al.,
2013 ULB, Brussels
H9-GFP
Mouse ESC E14 line stably transduced
with GFP
E14 original line obtained from
Baygenomics E14-GFP line was generated
by Gaspard et al., 2008, ULB, Brussels
E14-GFP
Human Tau Ex10+16 mutation (Tau*) line
11028V97
Wray, S. and Hardy, J., UCL, London 11028V97
Human Tau Ex10+16 mutation (Tau*) line
11028V98
Wray, S. and Hardy, J., UCL, London 11028V98
Experimental Models: Organisms/Strains
(WT mice) APP PS1 wt/wt Prkdc scid/scid This paper Prkdc scid/scid, The Jackson Laboratory,
Shultz et al., 1995, RRID:
IMSR_JAX:001303; APP PS1 wt/wt, Radde
et al., 2006, RRID: MGI:5313530
(AD mice) APP PS1 tg/wt Prkdc scid/scid This paper Prkdc scid/scid, The Jackson Laboratory,
Shultz et al., 1995, RRID:
IMSR_JAX:001303; APP PS1 tg/wt, Radde
et al., 2006, RRID: MGI:5313530
Software and Algorithms
STAR RNA-seq aligner Dobin et al., 2013 https://github.com/alexdobin/STAR
Subread/Featurecounts Liao et al., 2014 http://subread.sourceforge.net/
Pandas Python Data Analysis Library N/A http://pandas.pydata.org/
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Limma/Linear Models for Microarray Data Ritchie et al., 2015 https://bioconductor.org/packages/
release/bioc/html/limma.html
Benjamini-Hochberg algorithm Benjamini and Hochberg, 1995CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact Prof. Bart
De Strooper (bart.destrooper@vib.be).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human and Mouse Pluripotent Stem Cells
Experiments were performed using the H9 line stably expressing GFP under the control of chicken b-actin promoter (H9-GFP line)
generated previously (Espuny-Camacho et al., 2013), 2 iPSC lines carrying the Tau Ex10+16 mutation derived from one FTD patient
(Sposito et al., 2015) and the mouse E14 line stably expressing GFP under the control of the chicken b-actin promoter (E14-GFP line)
generated previously (Gaspard et al., 2008). Human and mouse pluripotent stem cells (PSC) lines were cultured and passaged on
mitotically inactivated mouse embryonic fibroblasts (MEFs) (Espuny-Camacho et al., 2013).
Karyotyping and CGH Array
The karyotyping of the iPSC Tau Ex10+16 lines was analyzed by Cell Guidance Systems (UK). For the CGH array analysis of the ESC
H9-GFP line, the genomic DNA was extracted using the QIAamp DNA Blood Mini QIAcube Kit on the Qiacube robotic workstation
according to the manufacturer’s instructions. Array analysis was performed using the 8x 60K CytoSure ISCA v2microarray (AMADID
020040, Oxford Gene Technology, OGT, Oxford, UK). Genomic DNA was labeled for 2 hr using the CytoSure Labeling Kit (Oxford
Gene Technology). The sample was labeled with Cy5 and hybridized versus Cy3-labeled sex-matched reference DNA. Hybridization
was performed for minimum 16 hr in a rotator oven (SciGene, CA, USA) at 65C.Washing of arrays was performed using Agilent wash
solutions with a Little Dipper Microarray Processor (SciGene). Arrays were scanned using an Agilent microarray scanner at 2 mm res-
olution, followed by calculation of signal intensities using Feature Extraction software (Agilent Technologies). Visualization of results
and data analysis was performed using the CytoSure Interpret Software (Oxford Gene Technology) and the circular binary segmen-
tation algorithm. Quality control metrics are monitored with CytoSure Interpret software (Oxford Gene Technology).
AD and WT Immunodeficient Mice
APP PS1 tg/wt mice (expressing KM670/671NL mutated APP and L166P mutated PS1 under the control of the Thy1.2 promoter1.1)
(Radde et al., 2006) were crossed with the immunodeficient NOD-SCIDmice (NOD.CB17-Prkdcscid) that carry a single point mutation
in the Prkdc gene (Shultz et al., 1995). APP PS1 tg/wt Prkdcscid/+ mice from the F1 generation were crossed with NOD-SCID mice to
generate APP PS1tg/wt Prkdcscid/scid immunodeficient mice. APP PS1 tg/wt Prkdcscid/scid mice were subsequently crossed with
NOD-SCID mice to generate either APP PS1 tg/wt Prkdcscid/scid (AD mice) or APP PS1 wt/wt Prkdcscid/scid (WT mice) used for trans-
plantations. Mice were housed in IVC cages in a SPF facility; light/dark cycle and temperature were alwaysmonitored. After weaning,
no more than 4 animals of the same gender were kept per cage.
The APP and PS1 genotyping was done as previously described (Radde et al., 2006). The Prkdc genotyping was done by PCR
amplification using the primers: Forward 50 GGA AAA GAA TTG GTA TCC AC 30; Reverse 50 AGT TAT AAC AGC TGG GTT GGC
30; followed by restriction digestion analysis of the amplicon with AluI enzyme (Roche Diagnostics). Products were analyzed on a
3% agarose gel.
Transplantation experiments were performed in bothmale and female littermates at P0. The total number of animals used for trans-
plantation and further analyses is indicated in Table S1. Mouse work was performed in accordance with institutional and national
guidelines and regulations, and following approval of the Ethical Committee of the KUL. All experiments conform to the relevant reg-
ulatory standards.
AD Human Brain Samples
Left hemisphere from 3 demented patients (patient 1: female, 60 years; patient 2: male, 65 years; patient 3: female, 70 years) clinically
diagnosed as ADwere taken at autopsy and fixed with formalin 10%. Tissue samples from several brain areas were further dissected
and embedded in paraffin for microscopic examination. The neuropathological analysis confirmed the presence of numerous neuro-
fibrillary tangles and senile plaques (Braak stage V-VI for neurofibrillary tangles, Thal stage 4 to 5 for Ab amyloid). Samples from the
frontal cortex and from the anterior hippocampus (approximately 3x3x1 cm) were cut in 10 mm thick coronal sections and used for
immunohistochemical analysis (Figures S3 and S7).e3 Neuron 93, 1066–1081.e1–e8, March 8, 2017
This study on post-mortem brain tissue was performed in compliance and following approval of the Ethical Committee of the
Medical School of the Free University of Brussels.
METHOD DETAILS
Pluripotent Stem Cell Differentiation into Cortical Cells
Human and mouse PSC cells were differentiated into cortical progenitors and neurons in vitro as previously described (Espuny-Ca-
macho et al., 2013). Briefly cells were dissociated manually or enzymatically using Stem-Pro Accutase on day-2, (Invitrogen A11105)
and plated on matrigel (BD, hES qualified matrigel) coated-coverslips/dishes at low confluency (5,000–10,000 cells/cm2) in MEF-
conditioned hES/hiPS medium supplemented with ROCK inhibitor (Y-27632; 10 mM Calbiochem, 688000). On day 0 of the differen-
tiation, themediumwas changed to DDM supplemented with B27 (10mLB27 per 500mLDDM,GIBCO) and Noggin (100 ng/ml, R&D
Systems) and the medium was replenished every 2 days. After 16 DIV, the medium was changed to DDM supplemented with B27
(GIBCO) and changed every 2 days. The cultures used for the experiments were routinely monitored for normal progenitor cell
proliferation and rosette radial glia formation in culture under phase-contrast microscope analysis. Cultures that underwent normal
parameters were used for transplantation experiments. At 14 DIV (for mouse PSC) and 24 DIV (for human PSC), the progenitors were
manually or enzymatically (Stem-Pro Accutase) dissociated and injected into newborn mice recipients. Some cultures were kept
in vitro after dissociation for cell identity analysis, resuspended in DDM supplemented with B27 and ROCK inhibitor (10 mM) and
plated onto poly-Lysin/Laminin coated coverslips. 5-7 days after dissociation, half of the medium was replenished with Neurobasal
supplemented with B27 (10 mL B27 per 500 mL DDM) and 2mM glutamine, and changed again every 5-7 days.
Intracerebral Grafting
Grafting experiments of human and mouse PSC-derived cortical progenitors and neurons were performed as previously described
(Gaspard et al., 2008; Espuny-Camacho et al., 2013) using the APP PS1 tg/wt NOD-SCID (AD mice) and APP PS1 wt/wt NOD-SCID
(WT mice) at P0. Briefly, human and mouse PSC-derived cortical progenitors and neurons were manually or enzymatically dissoci-
ated, supplemented with ROCK inhibitor (Y-27632; 10 mMCalbiochem, 688000) and injected into the frontal cortex of AD orWTmice.
Around 100.000 cells were injected in suspension. The total number of animals used for transplantation and further analyses is indi-
cated in Table S1.
Immunofluorescence and Confocal Microscopy
For IF analysis, mice were anesthetized with CO2 and perfused with phosphate-buffered saline followed by 4% paraformaldehyde
solution. The brain was then removed; post-fixed in the same fixative over 48-72 hr and cut into 60 mm slices on a Leica VT1000S
vibratome. IF on grafted brains was performed as described previously (Arranz et al., 2010; Espuny-Camacho et al., 2013) using pri-
mary and secondary antibodies (see Key Resources Table). Antigen retrieval was performed by microwave boiling the slides in
10 mM tri-Sodium Citrate buffer pH 6.0 (VWR). Nuclei staining was performed using a specific anti-human nuclei antibody (HuNuclei)
(see Key Resources Table), the pan-nuclear staining TOPRO3 (Invitrogen), or DAPI (SIGMA). Confocal Images were obtained using a
Nikon Ti-E inverted microscope equipped with an A1R confocal unit driven by NIS (4.30) software. The confocal was outfitted with
20x (0.75 NA), 40x oil (1.4 NA) and 60x oil (1.4 NA) objectives lenses. For excitation 405 nm, 488 nm, 561 nm, 638 nm laser lines
were used.
Immunohistochemistry
Mice were anesthetized with CO2, decapitated, and their brains were dissected and immersed in 10% (v/v) formalin for 24 hr. Brains
were embedded in paraffin, cut on aMicromHM360 slidingmicrotome at 6 mmandmounted. Sections were deparaffinized in xylene,
serially transferred to 100%, 90%, 70%, 50% ethanol solutions and rinsed. IHC was performed modifying the procedures described
previously (Arranz et al., 2010; Espuny-Camacho et al., 2013). Briefly, antigen retrieval was performed by boiling the slides at 120C
for 25 min in 10 mM Sodium Citrate buffer pH 6.0 (Sigma). After washing with Tris-buffered saline (TBS) buffer containing 0.1% (v/v)
Tween-20 (TBST), permeabilization and blocking were performed by incubating the sections at 4C for 12 hr with a blocking solution
containing 10%normal horse serum, 1%BSA, 0.1%gelatin and 0.3M glycine in TBST. Endogenous peroxidase activity was blocked
by incubation with 0.3% hydrogen peroxide (Sigma) in TBS 30 min at RT. Then, the slides were washed and incubated with blocking
solution containing 1% normal horse serum, 1%BSA, 0.1% gelatin and 0.3M glycine in TBST. After incubating with the primary anti-
body for 24 hr at 4C, slides were washed and incubated with the biotinylated secondary antibodies 1 hr at RT. Primary and second-
ary antibodies used for IHC are described in the Key Resources Table. The slides were washed and incubated for 1 hr in the ABC
solution (Vectastain Elite ABC kit, Vector Laboratories), and developed by using the ImmPACTTMDABPeroxidase Substrate Kit (Vec-
tor Laboratories). Optionally the slides were stained with hematoxylin and Congo Red (see protocol below), dehydrated andmounted
with DPX mounting medium (Sigma). Representative images were obtained using the Leica DM 2500M light microscope.
AT8 andMC1 IHCwere performed in serial sections with STEM121 IHC intended to determine the area of the human graft. AT8 and
MC1+ signals were analyzed as mouse host tissue or human grafted cells depending on the location of STEM121+ signals.Neuron 93, 1066–1081.e1–e8, March 8, 2017 e4
Electron Microscopy and Immunogold
The mice intended for EM analysis were perfused with 0.1 M phosphate buffer (PB) followed by fixative solution (2% paraformalde-
hyde, 2.5% glutaraldehyde in 0.1 M PB pH 7.4). Brains were removed, stored in the same fixative solution 3-4 days at 4C and then
cut into 60 mm slices on a Leica VT1000S vibratome. Areas comprising either the xenografts or the host tissue were dissected and
further processed for EM as described previously (Arranz et al., 2015). Briefly, tissue was washed overnight in PBS and post-fixed for
2 hr at RT with 1%OsO4, 1.5% K4Fe(CN)6 in 0.1 M PB. Sections were then rinsed and stained with 3% uranyl acetate for 1 hr at 4
C.
Dehydration was performed on ice by transferring the sections to 35%, 50%, 70%, 90% and 2 steps of 100% ethanol, followed by 2
steps of propylene oxide. The sections were embedded in EMbed812. Resin blocks comprising the xenografts or the host tissue
were sectioned on an ultramicrotome (Leica Ultracut UCT, Leica Microsystems). Semithin sections (1 mm) were collected on slides
and stained with 1% Toluidine blue solution (Sigma-Aldrich) and mounted in VectaMount mounting medium (Vector). Representative
areas were imaged under a light microscope (Leica DM 2500M). Ultrathin sections (70 nm) were mounted on copper grids and
imaged using a JEM-1400 transmission electron microscope (JEOL), equipped with an 11Mpixel Olympus SIS Quemesa camera
or with a Zeiss EM 809 transmission electron microscope.
When immunogold detection was needed, themice were perfused with a different fixative (2%paraformaldehyde and 0.2%glutar-
aldehyde in 0.1M PB pH 7.4). For immunolabelling, 60 mmbrain sections were first treated with 0.1% sodium borohydride for 30 min,
washed and incubated in blocking solution (4% goat serum in PBS) for 1 hr. After incubating with the primary antibodies (rabbit GFP
or mouse STEM121), sections were washed in 0.1% fish gel, 0.2%BSAc in PBS 2 times for 10 min. Sections were incubated with the
corresponding secondary antibodies (goat anti-mouse or goat anti-rabbit IgG conjugated to ultra-small gold particles of 0.8 nm)
diluted in 0.1% fish gel, 0.2% BSAc in PBS for 4 hr at RT. After post-fixation in 1% glutaraldehyde for 10 min, the immunogold signal
was intensified using a silver enhancement kit (HQ silver; Nanoprobes). Further processing of the tissue for EM was performed as
explained above.
Ab plaque Stainings
Ab plaques were detected either by immunostaining using 6E10 (Key Resources Table), or by staining with Thioflavin (SIGMA) or
Congo Red (SIGMA) to detect b sheet (aggregated state) conformations, as described previously (Radde et al., 2006). Briefly, for Thi-
oflavin staining brain sections were incubated with a filtered 0.05%aqueous Thioflavin-S (SIGMA) solution in 50%ethanol for 5min at
RT. After rinsing gradually with 70%, 95% ethanol and water, the sections were mounted with Glycergel (DAKO). When Congo Red
(SIGMA) was used to detect Ab plaques, paraffin slides were dipped with 1% Sodium Chloride Solution for 20 min at RT followed by
incubation in 1% Congo Red solution for 20 min. The slides were then dehydrated followed by xylene treatment and covered with
DPX mounting medium (Sigma-Aldrich).
TUNEL Apoptosis Assay
We used the Apop Tag Plus In situ apoptosis Fluorescein Detection Kit (Chemicon/Millipore) to detect apoptotic cell death. Vibra-
tome sections were first treated for antigen retrieval and immunostaining was performed as described above. Sections were then
immersed in 0.9% NaCl, washed and fixed in 4% paraformaldehyde. Sections were treated with proteinase K, washed, and post-
fixed in a mix of ethanol: acetic acid (2:1) at -20C. Sections were incubated with the Working Strength TdT enzyme for 1 hr at
37C. Next, sections were incubated with the Working Strength Stop/Wash Buffer at RT. Last, the Anti-Digoxigenin conjugate
was applied to the samples at RT. Sections were stained with DAPI and mounted on slides with Glycergel (DAKO).
Graft Dissection and RNA Extraction
Mice were sacrificed and quickly decapitated. The brain was dissected around themidbrain and the rostral part containing the cortex
was fixed to a platform for vibratome slicing into 300 mm brain sections at low speed 1, frequency 7-8. The buffer used was ice-cold
artificial CSF (Sucrose 212.5mM; KCl 3.5mM; NaHCO3 16mM; KH2PO4 1.2mM; Glucose 10mM; CaCL2 1mM;MgCl2 3mM) (SIGMA),
after CO2 equilibration. Slices were kept in artificial CSF/CO2 and further processed under a binocular fluorescence microscope to
dissect the GFP+ human graft tissue. Tissue pieces containing the human graft were collected into RNase free tubes and were snap
frozen in liquid nitrogen. Total RNA material was extracted using the QIAGEN Kit RNA easy, and eluted in RNase free water. RNA
concentration (ng/ml) and purity/quality (ratios 260/280 and 260/230) were quantified using Nanodrop spectrophotometer
technology.
RNA-seq Data Discrimination of Human Sequences in the Mixed Human + Mouse Sample
To ensure that we can reliably do RNA-seq on a sample containing both mouse and human RNA we mapped three datasets to
mouse, human and a mouse + human database. The three RNA-seq datasets we used were derived from:
1. Human brain samples, 50bp read length, single end (own data, not published).
2. Mouse hippocampus, 76bp read length, single end (own data, not published).
3. Simulated human data 100bp read length, single end (based on the human hg19 genome).
4. Simulated mouse data 100bp read length, single end (based on the mouse mm10 genome).e5 Neuron 93, 1066–1081.e1–e8, March 8, 2017
Each dataset is mapped to the mixed database and depending on the origin, the corresponding human or mouse only database,
using STAR RNA-seq aligner (Dobin et al., 2013) (same version, same parameters as used in this paper). For each mapping the
number of reads mapping with a quality score > 10 to each database genome was determined. This yielded the following data:Sample Raw Reads Mapped to Database Mapped to Organism % Mapped
hg19 mm10 hg19 mm10
A 2,069,030,113 hg19 1,393,960,897 N/A 67.4% N/A
A 2,069,030,113 hg19+mm10 1,347,734,447 10,196,128 65.1% 0.5%*1
B 210,668,268 mm10 N/A 188,764,921 N/A 89.6%
B 210,668,268 hg19+mm10 141,165 162,975,781 0.1%*1 77.4%
C 193,082,054 hg19+mm10 188,047,214 2 97.4% 0.0%*2
D 16,237,465 hg19+mm10 14 15,618,208 0.0%*2 96.2%Cross-Mapping
One major concern when mapping a mix of human + mouse RNA to a RNA-seq database containing both human and mouse is that
reads might accidentally map to the wrong genome. These results show that the percentage of cross mapping reads is very low. The
(non-simulated) human and mouse material show a cross-mapping ratio of 0.5% and 0.1% (*1). The simulated human and mouse
material do not cross-map at all (*2). The difference between the simulated and non-simulated data can be explained by (a) the
non-simulated data has shorter read lengths (also shorter than the 100bp used in the paper) and (b) the fact that real biological
data will contain genomic differences to the reference genome, adding to the potential to cross-map. It is therefore logical to assume
that the cross-map percentage for the experiment in this paper will be better than the biological samples (A+B, due to the longer read
length), but not as good as the artificial samples (C+D, due to the genomic variation).
Fraction of Reads Mapping
By selecting only reads that map with a quality score of 10 or better, we strongly select against reads which cannot be mapped to a
unique location in the genome (using either the organism specific database or the mixed database) preventing cross-mapping. It is
however possible that this drastically reduces the number of reads able to map, and hence reduces sensitivity of measuring of
expression. We can assess this by checking how many reads map (of sample A+B) when mapped to the corresponding genome,
and compare these numbers to the number of readsmapping to themixed database. For sample A (human) we lose 2.3%of all reads
(67.4%–65.1%). In the mouse sample we lose 12.2% (89.6%–77.4%). However, in both cases a very respectable amount of reads is
still able to map uniquely to the genome. This data shows that it is possible to reliably map an RNA-seq dataset derived from mixed
human and mouse sample.
QUANTIFICATION AND STATISTICAL ANALYSIS
Morphological Analysis for Quantification
Morphometry and measurements were performed with Fiji/ImageJ software. For quantifications, at least 4-5 different brain sections
comprising the human xenografts and the adjacent mouse host tissue were included per animal.
Immunofluorescence (IF) sections were imaged by confocal microscopy (Nikon Ti-E inverted microscope) with a 20x (0.75 NA)
objective to image Z series stacks of areas inside human xenografts or mouse host tissue (8-10 optical sections 1 mm apart for
each image). All images were acquired using identical acquisition parameters as 16-bit, 1024x1024 arrays. Z series stacks were
then converted in Fiji/ImageJ to maximum intensity projections and threshold adjusted to isolate specific fluorescence.
Immunohistochemistry (IHC) sectionswere imaged using a Leica DM2500M light microscopewith a 63x objective. All imageswere
acquired using identical acquisition parameters as 16-bit, 1024x1024 arrays.
Ultrathin EM sections comprising either the human xenografts or the adjacent mouse host tissue were imaged using a JEM-1400
transmission electronmicroscope (JEOL) equippedwith a 11M-pixel Olympus SISQuemesa camera. Imageswere taken in randomly
selected areas at a 600x magnification.
Quantification of Ab Plaque Burden
The mean area of Ab plaques and the number of Ab plaques per area was manually determined on IF images using Fiji/ImageJ.
Results are shown for mouse host (n = 5) and human grafts (n = 5) in ADmice 4MPT. Data are represented asmean ± SEM. Statistical
analysis were done with Student’s t test.
Statistical details of experiments can be found in Figure 1 and related figure legend.Neuron 93, 1066–1081.e1–e8, March 8, 2017 e6
Quantification of Neuroinflammation
The number of Iba1+ andGFAP+ cells per areawas quantifiedmanually on IF images in 4 different blindly set areas. Results are shown
for mouse host fromWTmice (n = 3 animals 4MPT; n = 4 6MPT); mouse host from ADmice (n = 3 animals 4MPT; n = 4 6MPT); human
grafts from WT mice (n = 3 animals 4MPT; n = 4 6MPT); human grafts from AD mice (n = 3 animals 4MPT; n = 4 6MPT). Data are
represented as mean ± SEM. Statistical analysis was done with two way-ANOVA with Bonferroni posttests.
The percentage of hypertrophic and/or phagocytic astrocytes and microglia cells was calculated on EM images manually with Fiji/
ImageJ. Results are shown for human grafts in WT mice (n = 3) and human grafts in AD mice (n = 3) 6MPT. Data are represented as
mean ± SEM. Statistical analysis were done with Student’s t test.
Statistical details of experiments can be found in Figure 2 and related figure legend.
Quantifications of Ubiquitin+, SYP+, and VGlut1+ DNs
The percentage of Ab plaques surrounded by Ubiquitin+, SYP+ and VGlut1+ DNs was manually determined on IF images using Fiji/
ImageJ. Ubiquitin results are shown for mouse host from AD mice (n = 5) and human grafts from AD mice (n = 5). SYP and VGlut
results are shown for mouse host from AD mice (n = 5) and human grafts from AD mice (n = 5 and n = 4, respectively). Data are rep-
resented as mean ± SEM. Statistical analysis were done with Student’s t test.
Statistical details of experiments can be found in Figure 3 (for Ubiquitin), Figure 4 (for SYP and VGlut) and related figure legends.
Quantification of Cell Density
Abplaques on IF imageswere visualized asmasks (examples of Abmasks used for Figures 5E and 5K shown in Figures S4GandS4H)
and consequently a total area from the center of the plaque was drawn, akin to a Scholl analysis but with variable borders. The area
was increased from the original detectedmask of the plaques by a factor 50. Touching areas were fused and areaswere calculated at
each step. Nuclei were counted manually inside the areas and cell density was expressed as the number of nuclei per area. Data is
represented as the%of relative cell density of AD versusWTmice. Quantification was performed at 2MPT or 6MPT: human grafts/AD
mice (n = 4mice 2MPT; n = 4 6MPT); human grafts/WTmice (n = 3mice 2MPT; n = 4 6MPT); mouse host/ADmice (n = 4); mouse host/
WTmice (n = 4); human Tau* grafts/ADmice (n = 3mice 6MPT); human Tau* grafts/WTmice (n = 3mice 6MPT). Data are represented
as mean ± SEM. Statistical analysis was done following one way-ANOVA with Bonferroni posttests.
In addition, the neuronal density and the percentage of degenerating necrotic neurons were calculated manually on EM images
using Fiji/ImageJ. Results are shown for mouse host in WT mice (n = 3), mouse host in AD mice (n = 3), human grafts in WT mice
(n = 3) and human grafts in AD mice (n = 3). Data are expressed as mean ± SEM. Statistics were performed by two way-ANOVA
with Bonferroni posttests.
Statistical details of experiments can be found in Figure 5 and related figure legend.
Quantification of the Percentage of 4R Tau+ Cells
The percentage of 4R Tau+/GFP+ cells (in human grafts) or 4R Tau+/HuNCAM+ cells (in human Tau* grafts) was manually determined
on IF images using Fiji/ImageJ. Results are shown for human grafts 4MPT (n = 3) and 6MPT (n = 6 mice); human Tau* grafts 4MPT
(n = 4) and 6MPT (n = 2 mice). Data are expressed as mean ± SEM. Statistical analysis was done following two way-ANOVA with
Bonferroni posttests.
Statistical details of experiments can be found in Figure 6 and related figure legend.
Quantification of the Percentage of Ab Plaques Surrounded by AT8 or MC1+ DNs
The proportion of Ab plaques surrounded by AT8+ or MC1+ DNs was determined manually on IHC images with Fiji/ImageJ. Results
are shown for human grafts (n = 4 mice), human Tau* grafts (n = 3) and mouse host tissue (n = 3) in ADmice. Data are represented as
mean ± SEM. Statistical analysis was done following one-way ANOVA with Kruskal-Wallis test.
Statistical details of experiments can be found in Figure 7 and related figure legend.
RNA-Seq Data Analysis
RNA samples of high quality and high RIN values (8-10) (RNA stability) were used for this study. 7 samples containing human grafted
cells transplanted into AD animals and 7 samples of human grafted cells transplanted intoWT animals were analyzed 4-5MPT. 5 sam-
ples containing human grafted cells transplanted into AD animals and 2 samples of human grafted cells transplanted intoWT animals
were analyzed 8MPT. The extracted RNA was analyzed by the VIB nucleomics core (http://www.nucleomics.be/) which generated
polyA RNA-seq libraries using the Illumina Truseq stranded mRNA library prep protocol (Protocol 15031047 Rev E_October 2013).
The libraries were sequenced on an Illumina Nextseq 500 sequencer, generating 100bp single-end reads. Raw reads were mapped
to a combined database of the mouse (GRCm38/mm10) and human genome (hg19, gencode19) using the STAR RNA-seq aligner
(version 2.4.2a) (Dobin et al., 2013). Raw read counts were determined using the FeatureCounts software (Liao et al., 2014) with a
GTF file combining the human and mouse annotation with an alignment quality cutoff of 10.e7 Neuron 93, 1066–1081.e1–e8, March 8, 2017
Differential Expression Analysis
Prior to differential expression analysis we performed a PCA analysis on the normalized counts and manually removed obvious
outliers (leaving a total of 7 AD samples, 5 WT samples at 4-5MPT and 5 AD samples, 2 WT samples at 8MPT). Sequenced RNA
from the combined mouse & human material was mapped back to a joint database of the human and mouse genome. The genomic
differences between mouse and human allowed us to reliably separate human from mouse reads (explained above) and perform an
independent differential expression analysis of the human and mouse expression data in both the young and old mice. Differential
expression analysis was performed for the early and late stage samples using edgeR (Robinson et al., 2010) comparing samples
from APP/PS1 mice to WT mice.
Enrichment Analysis
A set of GO categories related to AD was collected based on the GO ontology (2016-02-10) and human gene annotations (2016-02-
16). GO categories related to ADwere manually selected excluding overlapping, as well as small and large sets. Co-expression gene
sets as defined by (Zhang et al., 2013) were extracted from their supplemental data. To assess to what extent the expression patterns
from our human neurons are comparable to the networks identified by Zhang et al., we performed a co-expression clustering analysis
using WCGNA (Langfelder and Horvath, 2008) on our data. This approach yield modules of genes showing a similar expression
pattern across samples, comparable to the modules identified by Zhang et al. To perform the WCGNA analysis we used the normal-
ized counts from the differential expression analysis as input and filtered out the lowest expressing genes, leaving 14632 genes. We
then runWCGAwith the power parameter set to 5. This yields 33 genemodules. Tomore directly compare the differential expression
results, we add 4 gene sets containing the 1000 most up and downregulated genes from the young and old mice. The overlap of
genes of these 37 modules with all modules identified by Zhang et al. is determined by a fisher exact test, with as background all
genes which are a part of both our modules as well as the Zhang modules. The p values of the 2442 comparisons are corrected
for Multiple testing using the Benjamini Hochberg (Benjamini and Hochberg, 1995) approach.
Determination of Tau Splice Form Usage
Raw junction counts as generated by the STAR aligner (Dobin et al., 2013) were collected. The raw junction counts were normalized
for library size using Limma Voom (Ritchie et al., 2015). From the complete table of splice forms the normalized junction counts of
MAPT exon 9-10 (X9,10, hg19, chr17, position 44074031 to 44087675), 9-11 (X9,11, chr17, position 44074031 to 44091608) and
10-11 (X10,11, chr17, position 44087769 to 44091608) were extracted. The 3R splice form is represented by the junction 9-11 and
4R by both 9-10 and 10-11. The percentage of MAPT 4R usage was subsequently calculated by: 100 * (X9,11) / (0.5 * (X9,10 +
X10,11)) and visualized in a boxplot. A total of 7 AD samples and 5 WT samples at 4-5MPT; and 5 AD samples, and 2 WT samples
at 8MPT were used for the analysis.
DATA AND SOFTWARE AVAILABILITY
RNA-seq raw read counts determined by Featurecount software of humanPSC-derived neurons grafted into the cortex of AD andWT
mice are available in Table S6. RNA-seq raw read counts determined by Featurecount software ofmurine AD andWT cortex are avail-
able in Table S7. The Software tools used for the RNA-seq analysis in this study are the following: STARRNA-seq aligner (Dobin et al.,
2013), available in https://github.com/alexdobin/STAR; Subread/Featurecounts (Liao et al., 2014), available in http://subread.
sourceforge.net/; Pandas Python Data Analysis Library, available in http://pandas.pydata.org/; Limma / LinearModels for Microarray
Data, (Ritchie et al., 2015), available in https://bioconductor.org/packages/release/bioc/html/limma.html; and Benjamini-Hochberg
algorithm (Benjamini and Hochberg, 1995).Neuron 93, 1066–1081.e1–e8, March 8, 2017 e8
